Spots Global Cancer Trial Database for A Study of BMS-863233 in Patients With Hematologic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of BMS-863233 in Patients With Hematologic Cancer
Official Title: A Phase 1/2, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Refractory Hematologic Malignancies
Study ID: NCT00838890
Conditions
Study Description
Brief Summary: To determine safety, tolerability and maximum tolerated dose of BMS-63233/XL413 in subjects with Refractory Hematologic Cancer
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University Of Miami, Miami, Florida, United States
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Roswell Park, Buffalo, New York, United States
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
